ESMO 2024 | 5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
Jonathan Rosenberg
• 16 Sep 2024
Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of updated 5-year results from the EV-103 trial (NCT03288545), which assessed enfortumab vedotin (EV) plus pembrolizumab in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (la/mUC). With a manageable safety profile, the combination showed promising efficacy, and these results affirm EV and pembrolizumab as a durable first-line therapy for la/mUC. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
